Menopausal Hormone Therapy (HRT) and Breast Cancer Risk has been in the news. Find out what you may need to clarify with your health care provider.

MHT and Breast Cancer Risk – Lancet

What is the name of the paper about MHT and Breast Cancer Risk published in The Lancet on 29 August 2019?

The name of the paper is Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta Analysis of the Worldwide Epidemiological Evidence.

Interpretation

In this paper, what was the Interpretation?

In Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta Analysis of the Worldwide Epidemiological Evidence: Summary the interpretation stated?

“Interpretation If these associations are largely causal, then for women of average weight in developed countries, 5 years of MHT, starting at age 50 years, MHT and Breast Cancer RiskMHT and Breast Cancer Riskwould increase breast cancer incidence at ages 50–69 years by about one in every 50 users of oestrogen plus daily progestagen preparations; one in every 70 users of oestrogen plus intermittent progestagen preparations; and one in every 200 users of oestrogen-only preparations. The corresponding excesses from 10 years of MHT would be about twice as great”.

IMS Response

What did the International Menopause Society’s (IMS) response to this paper include?

MHT and Breast Cancer RiskOn page one in The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience” the IMS elaborate on:

“Is there new information that menopausal hormone therapy (MHT) substantially increases breast cancer risk as suggested by a paper published in the Lancet this month and should women be worried?

  • Much of the information regarding breast cancer risk and MHT reported in this paper is not new…
  • It is important to note that, because of when the data included in this report was collected, most of the MHT regimes were different from those used today
  • This paper provides an important public health message about obesity and breast cancer risk…”.

AMS Response

What did the Australasian Menopause Society (AMS) (Australia and New Zealand) response to this paper include?MHT and Breast Cancer Risk

In MHT and Breast Cancer Risk the AMS elaborate on:

“It is extremely important to note that this paper does not inform us of the impact of current recommended MHT prescribing practices on breast cancer risk”.

BMS Response

What did the British Menopause Society’s (BMS) MHT and Breast Cancer Riskresponse to this paper include?

In BMS Response To Lancet Paper on the Link Between Different Forms of HRT and Breast Cancer Incidence the BMS elaborate on:

“The overall findings from this study are in keeping with the NICE Menopause guideline recommendations which show a small increase in risk of breast cancer with HRT. Women must be informed of the data on breast cancer risk with HRT to help them make an informed decision. This should also be considered in comparison to the risk of breast cancer with other lifestyle factors such as alcohol intake and obesity which have been shown to be associated with a higher risk compared to that with HRT. This should also be taken in the context of the overall benefits obtained from using HRT including symptom control and improving quality of life as well as considering the bone and cardiovascular benefits associated with HRT use”.

What is HRT?

HRT can be an abbreviation for Hormone Replacement Therapy.

Summary

Is there a summary of this paper?

MHT and Breast Cancer RiskYour Country may have a summary similar to the (United Kingdom) NHS’s (National Health Service) Study Suggests HRT Carries Higher Risk of Breast Cancer Than Thought.

Health Care Provider

In response to this paper, what are Recommendations from the IMS?

On page two in The International Menopause Society Comment on: “Type and Timing of Menopausal Hormone Therapy and Breast Cancer Risk: Individual Participant Meta-Analysis of the Worldwide Epidemiological Experience” the IMS state:

“Recommendations From the IMS

Women enter menopause across a range of ages, with diverse symptoms and health risk profiles. The International Menopause Society advocates the comprehensive assessment of women, including attention to modifying risk factors for chronic disease such as being overweight or obese, the importance of which have been highlighted in this Lancet paper. The benefits and risks of MHT differ according to the timing of menopause such that individualisation of therapy is essential. As prescribing practices have changed significantly over the last decade, further research is needed to determine the impact of currently recommended regimens”.

In Menopause Experts Dismiss Some Breast Cancer Claims In New Report the JH elaborate on:

“Australian menopause experts are urging women to talk to their doctor about their use of menopausal hormone therapy (MHT) if they have concerns following today’s publication of a large study linking MHT to an increased risk of breast cancer”.

Links

Where may I find Links related to MHT and Breast Cancer Risk?

Your Country may have Links similar to:

Health Topics A-Z

Where may I find Health Topics related to MHT and Breast Cancer Risk?

In Health Topics A-Z you may find:

Meno Martha
Last Updated: 24 November 2019 – Last Revised: 09 September 2019
image_pdf